Mark C. Griffiths to Lead CARBOGEN AMCIS’ Growth12 July 2011
BUBENDORF, Switzerland (July 12, 2011) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced that Mark C. Griffiths has been named chief executive officer, effective today. In his new role, Griffiths will have responsibility for the CARBOGEN AMCIS’ Swiss business and will report to Jay Vyas, managing director of Dishman Pharmaceuticals and Chemicals Ltd., CARBOGEN AMCIS’ parent company.
Mark C. Griffiths has been associated with CARBOGEN AMCIS as director of operations and chief executive officer for almost ten years. Most recently, he has been working for the Dishman Group as operations advisor overseeing the design and construction of the group’s large-scale manufacturing facilities for commercial supply of Highly Potent APIs (HPAPIs) in Shanghai, China, and Ahmedabad, India.
“We are delighted that Mark agreed to join CARBOGEN AMCIS as chief executive officer,” commented Jay Vyas. “Mark’s industrial expertise and proven track record in the pharmaceutical industry make him the ideal executive to lead CARBOGEN AMCIS’ growth. We are confident in Marks’ ability to accelerate the success of our company and our customers by maintaining the focus on high performance.”
Griffiths has over 28 years of relevant industrial experience delivering high added value technical and operational solutions within the pharmaceutical and fine chemical industry.
Qualified as an engineer and having gained significant experience in the management of complex, multi-task, multi-input projects, he brings a cross-functional ability to anticipate and optimize technical, operational and management issues. Griffiths has designed, built and managed facilities ranging in function from research and development to manufacturing.
Griffiths holds a Master of Science in engineering from Bristol University, UK.
CARBOGEN AMCIS AG is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.
Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and commercial API manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.